| Literature DB >> 33561292 |
Paolo Enrico1, Giuseppe Delvecchio1, Nunzio Turtulici1, Alessandro Pigoni2, Filippo Maria Villa3, Cinzia Perlini4, Maria Gloria Rossetti5,6, Marcella Bellani5,7, Antonio Lasalvia5,7, Chiara Bonetto5, Paolo Scocco8, Armando D'Agostino9, Stefano Torresani10, Massimiliano Imbesi11, Francesca Bellini12, Angela Veronese8, Luisella Bocchio-Chiavetto13,14, Massimo Gennarelli13,15, Matteo Balestrieri16, Gualtiero I Colombo17, Annamaria Finardi18, Mirella Ruggeri5,7, Roberto Furlan18, Paolo Brambilla1,6.
Abstract
For several years, the role of immune system in the pathophysiology of psychosis has been well-recognized, showing differences from the onset to chronic phases. Our study aims to implement a biomarker-based classification model suitable for the clinical management of psychotic patients. A machine learning algorithm was used to classify a cohort of 362 subjects, including 160 first-episode psychosis patients (FEP), 70 patients affected by chronic psychiatric disorders (schizophrenia, bipolar disorder, and major depressive disorder) with psychosis (CRO) and 132 health controls (HC), based on mRNA transcript levels of 56 immune genes. Models distinguished between FEP, CRO, and HC and between the subgroup of drug-free FEP and HC with a mean accuracy of 80.8% and 90.4%, respectively. Interestingly, by using the feature importance method, we identified some immune gene transcripts that contribute most to the classification accuracy, possibly giving new insights on the immunopathogenesis of psychosis. Therefore, our results suggest that our classification model has a high translational potential, which may pave the way for a personalized management of psychosis.Entities:
Keywords: immune biomarkers; immunity; machine learning; personalized medicine; psychosis; transcriptomics
Mesh:
Year: 2021 PMID: 33561292 PMCID: PMC8266656 DOI: 10.1093/schbul/sbaa190
Source DB: PubMed Journal: Schizophr Bull ISSN: 0586-7614 Impact factor: 9.306